Edward Miracco, Ph.D.

Head, Enterprise AI Enablement at Moderna, Inc.

Speaker

When I first learned of pseudouridine, I was intrigued by its ubiquity yet lack of functional understanding. This led me to pursue a graduate degree in the mechanistic enzymology of RNA editing, and more specifically of the pseudouridine synthases. I continued my connection to pseudouridine with a cryoEM post-doc on telomerase, and during this time, key papers were published on mRNA containing pseudouridine leading to dramatic increases to protein production and decreases in immune activation. I joined the mRNA process development group at Moderna in early 2014 and have held roles in LNP process development, Quality, RNA chemical biology, and now reinventing the whole stack through the use of AI.